ProMIS Neurosciences Inc., a clinical-stage biotechnology company, has announced its participation at the Alzheimer's Association International Conference 2025, where it will present its ongoing PRECISE-AD trial in Alzheimer's Disease (AD) and its Discovery Platform, EpiSelectTM. The presentation will include information on the company's Phase 1b clinical trial, which investigates the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PMN310 in patients with early Alzheimer's Disease. The company is progressing with trial enrollment following a DSMB recommendation to proceed to the second dose level. Results from this trial and details about the platform will be shared during various sessions at the conference, with abstracts available on ProMIS Neurosciences' website following the presentations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.